Duality Biotherapeutics signs Genentech pact for next-generation ADCs, gets US$45 million upfront

• Duality Biotherapeutics entered a global R&D collaboration with Roche unit Genentech on Aug. 27, 2026 to develop next-generation oncology ADCs.
• Programs will use DualityBio’s DUPAC novel-payload platform, targeting selected oncology indications.
• DualityBio will lead discovery, then early global clinical development through Phase 1a.
• Genentech gets an exclusive worldwide license to resulting ADCs, then takes over further development, manufacturing, commercialization post-Phase 1a.
• Deal includes USD 45 million upfront, over USD 1 billion potential milestones, tiered royalties on annual net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12303671), on August 27, 2026, and is solely responsible for the information contained therein.